Alessandro Galbiati

机构：Pharma Nord (United Kingdom), Nerviano Medical Sciences, Acacia Pharma (United Kingdom) · ORCID：0000-0002-8795-7934

发表论文 90 篇 · 总被引 1130 次 · h-index 14

代表论文

• Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair (2025 · NAR Cancer · 被引 6)
• Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy (2025 · Nucleic Acids Research · 被引 3)
• Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor (2025 · Journal of Medicinal Chemistry · 被引 3)
• Abstract 2905: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors (2025 · Cancer Research · 被引 2)
• Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1 (2025 · Journal of Medicinal Chemistry · 被引 1)
• 139 (PB127): ART6043: a first-in-class clinical DNA Polymerase Theta polymerase domain inhibitor for potentiating PARP inhibitor efficacy (2024 · European Journal of Cancer · 被引 1)